Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Dermatology

Long-Term Care and Daily Management

At a Glance

IgA pemphigus can return after periods of clear skin, so long-term care focuses on controlling flares, protecting open areas, and monitoring dapsone or steroid side effects. Regular follow-up helps tailor treatment and decide whether symptoms warrant evaluation for associated conditions.

Important Note: This guide is designed to help you understand your diagnosis and communicate effectively with your medical team. It does not replace an individualized dermatologist’s assessment. Never start, stop, or alter your doses of dapsone or systemic steroids without speaking to your prescriber.

Because IgA pemphigus is a chronic condition, the goal of long-term care is to maintain clear skin while monitoring for potential medication side effects and addressing your day-to-day comfort. While the diagnosis can feel overwhelming, understanding what to watch for allows you to stay ahead of the disease.

Long-Term Expectations and Remission

IgA pemphigus typically follows a chronic relapsing course [1]. This means you may experience years of clear skin followed by occasional flares where the pustules reappear.

  • Prognosis: IgA pemphigus is generally a skin-limited disease, and the overall prognosis varies by individual. While published disease-specific outcome data are limited, one study in a broader atypical pemphigus cohort reported a low mortality rate of around 4% [2].
  • Management Goals: Treatment responses vary; while some patients may respond to dapsone alone, others require alternative regimens or low-dose corticosteroids, and many achieve significant clinical improvement [1].

Evaluating for Associated Conditions

In the medical literature, IgA pemphigus is sometimes seen alongside other conditions. These associations are rare, and this does not mean you are likely to develop them or that every patient needs routine cancer surveillance. Evaluation should be individualized based on your history, examination, and specialist judgment.

1. IgA Monoclonal Gammopathy

Some patients with IgA pemphigus have a condition where the body produces too much of a specific IgA protein, known as monoclonal gammopathy [3]. In very rare instances in the literature, this has been reported with multiple myeloma [4].

  • Surveillance: If you have abnormal baseline labs or specific symptoms, your doctor may order tests like Serum Protein Electrophoresis (SPEP) or free light chain blood tests to evaluate these protein levels [5].
  • When to speak up: Tell your doctor if you experience unexplained bone pain, extreme fatigue, or frequent infections, as these can prompt a symptom-based evaluation [6].

2. Ulcerative Colitis (UC)

There is a documented link between IgA pemphigus and ulcerative colitis, an inflammatory bowel disease [3].

  • Signs to watch for: Persistent diarrhea, blood or mucus in your stool, urgency to go to the bathroom, or unexplained weight loss [7].
  • Monitoring: If these symptoms occur, your doctor may use a stool test called fecal calprotectin to check for gut inflammation before referring you to a gastroenterologist [8].

Daily Skin Management and Wound Care

When pustules rupture, they leave raw areas that must be protected to prevent infection and promote healing. Here is a practical flare plan:

  • Sterile vs. Infected: Remember that your pustules are usually “sterile”, but they can become infected by bacteria [9].
  • Cleaning: Gently cleanse the area with mild, fragrance-free soap and water. Avoid aggressive scrubbing, which can cause more blisters (the Nikolsky sign).
  • Dressings: Use nonadherent (non-stick) dressings selected with your clinician to protect open areas. While some research in other pemphigus populations suggests specialized dressings like those containing silver may help wounds heal [10], these can sometimes irritate wounds and should only be used if specifically directed by your wound-care professional.
  • Itch Management: Use cool compresses, wear loose clothing, and apply gentle fragrance-free skin care. Ask your clinician about safe antipruritic treatments.

Managing Treatment Side Effects

Long-term use of medications requires an individualized surveillance framework to keep you safe.

  • Dapsone: You will need regular clinician-directed blood counts (CBC) and liver function tests. Watch for signs of anemia, such as feeling unusually winded when walking up stairs, and report them to your doctor [11][12].
  • Steroids: Long-term use can affect bone density and blood sugar. Your doctor may recommend periodic bone density scans (DEXA) or blood sugar monitoring [13].

Follow up with your team regularly, focus on managing your current skin health, and maintain open communication with your specialists.

Common questions in this guide

How does IgA pemphigus usually behave over time?
IgA pemphigus often has a chronic, relapsing course, meaning periods of clear skin can be followed by flares with new pustules. It is generally limited to the skin, but the outlook and response to treatment vary from person to person.
What should I do when an IgA pemphigus pustule breaks open?
Clean the area gently with mild, fragrance-free soap and water, and avoid scrubbing because irritation can trigger more blistering. A clinician-recommended nonstick dressing can protect the raw area. Pustules are usually sterile but can become infected, so report concerning changes to your care team.
What tests are needed while I take dapsone for IgA pemphigus?
Your clinician may schedule regular complete blood counts and liver function tests while you take dapsone. Report unusual shortness of breath or feeling very winded, which can be a sign of anemia, and follow your prescriber's monitoring schedule.
How can I monitor risks from long-term steroid treatment?
Long-term systemic steroids can affect bone strength and blood sugar. Your clinician may recommend periodic bone-density testing and blood-sugar checks based on your dose, duration, and health history.
Do I need screening for cancer or monoclonal gammopathy with IgA pemphigus?
Associations with monoclonal gammopathy are uncommon, and a rare report has linked IgA pemphigus with multiple myeloma; this does not mean every patient needs routine cancer screening. Your doctor may consider serum protein electrophoresis or free light-chain testing when your history, examination, symptoms, or baseline lab results support it.
What bowel changes should I report if I have IgA pemphigus?
Tell your doctor about persistent diarrhea, blood or mucus in your stool, urgency, or unexplained weight loss. These symptoms can prompt evaluation for ulcerative colitis, sometimes beginning with a stool test called fecal calprotectin and a referral to gastroenterology.
What can help with itching during an IgA pemphigus flare?
Cool compresses, loose clothing, and gentle fragrance-free skin care may reduce discomfort. Ask your clinician which anti-itch treatment is safe for you, especially if skin is open or you use other medicines.

Get notified when new evidence is published on IgA pemphigus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Case Report: A rare co-occurrence of IgA pemphigus and pyoderma gangrenosum associated with IgA-κ type monoclonal gammopathy of undetermined significance: a 19-year diagnostic and therapeutic journey.

    Xie Y, Liu X, Wu J, et al.

    Frontiers in immunology 2026; (17()):1832860 doi:10.3389/fimmu.2026.1832860.

    PMID: 42245644
  2. 2

    A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study.

    Quintarelli L, Bonanni I, Mariotti EB, et al.

    Clinical and experimental dermatology 2026; (51(2)):250-262 doi:10.1093/ced/llaf438.

    PMID: 41072932
  3. 3

    IgA pemphigus: A systematic review.

    Kridin K, Patel PM, Jones VA, et al.

    Journal of the American Academy of Dermatology 2020; (82(6)):1386-1392 doi:10.1016/j.jaad.2019.11.059.

    PMID: 31812619
  4. 4

    Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: A case report and literature review.

    Koga H, Tsutsumi M, Teye K, et al.

    The Journal of dermatology 2023; (50(2)):234-238 doi:10.1111/1346-8138.16516.

    PMID: 35838241
  5. 5

    Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.

    Willrich MA, Katzmann JA

    Clinical chemistry and laboratory medicine 2016; (54(6)):907-19.

    PMID: 26509779
  6. 6

    Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review.

    Liu Y, Parks AL

    JAMA internal medicine 2025; (185(4)):450-456 doi:10.1001/jamainternmed.2024.8124.

    PMID: 39960681
  7. 7

    THE ONSET OF CLINICAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS.

    Nóbrega VG, Silva INN, Brito BS, et al.

    Arquivos de gastroenterologia 2018; (55(3)):290-295 doi:10.1590/S0004-2803.201800000-73.

    PMID: 30540094
  8. 8

    Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity.

    Nakov RV, Nakov VN, Gerova VA, Tankova LT

    Folia medica 2019; (61(2)):188-196.

    PMID: 31301663
  9. 9

    Profile of Cutaneous Bacterial Flora in Pemphigus Patients.

    Mohanty S, Saha S, Firdaus S, Sirka CS

    Journal of laboratory physicians 2023; (15(4)):616-620 doi:10.1055/s-0043-1768635.

    PMID: 37780880
  10. 10

    A preliminary clinical trial comparing wet silver dressings versus wet-to-dry povidone-iodine dressings for wound healing in pemphigus vulgaris patients.

    Chen J, Zou Q, Hamblin MR, Wen X

    Dermatologic therapy 2021; (34(3)):e14906 doi:10.1111/dth.14906.

    PMID: 33611826
  11. 11

    Dapsone induced hemolysis and drop in saturation in normal glucose-6-phosphate dehydrogenase level patients - alarming presentation of poor man's drug: A series of 12 cases and review of literature.

    Pradhan S, Dash G

    Indian journal of pharmacology 2026; (58(4)):468-471 doi:10.4103/ijp.ijp_1323_25.

    PMID: 42583982
  12. 12

    Clinical Indicators Suggesting Dapsone-Induced Methemoglobinemia in Dermatology Outpatients: A Pilot Retrospective Cohort Study.

    Mathews J, Thomas A, Lekshmi S P, et al.

    Cureus 2026; (18(6)):e111188 doi:10.7759/cureus.111188.

    PMID: 42333280
  13. 13

    Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review).

    Costan VV, Popa C, Hâncu MF, et al.

    Experimental and therapeutic medicine 2021; (22(5)):1335 doi:10.3892/etm.2021.10770.

    PMID: 34630689

This page is for informational purposes only and does not constitute medical advice or replace an individualized assessment by your dermatologist. Do not start, stop, or change dapsone or steroid treatment without speaking with your prescriber.